hydroxyurea has been researched along with Hyperpigmentation in 23 studies
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea is a cytostatic agent used in patients with myeloproliferative disorders that may produce nail hyperpigmentation, most frequently longitudinal melanonychia." | 7.70 | Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. ( de Unamuno, P; Hernández-Martín, A; Ros-Forteza, S, 1999) |
| "Hydroxyurea is a chemotherapeutic agent that is used in the treatment of various hematological diseases including chronic myelogenous leukemia, polycythemia vera, and sickle cell anemia." | 5.51 | Hydroxyurea-induced hyperpigmentation with iron deposition. ( Klimas, NK; Koshelev, MV; Lee, KP; Sanyal, S; Vangipuram, RK, 2019) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 5.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
| "Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation." | 3.74 | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. ( Chimenti, S; Saraceno, R; Teoli, M, 2008) |
| "A 47-year-old male developed both longitudinal melanonychia and periungual hyperpigmentation 6 months after initiation of hydroxycarbamide (synonym: hydroxyurea) therapy for chronic myeloproliferative disease." | 3.74 | Nail pigmentation due to hydroxycarbamide. ( Ceulen, RP; Frank, J; Poblete-Gutiérrez, P, 2007) |
| "We report three male patients, with duplex confirmed chronic venous disease, who were on treatment with hydroxyurea for chronic myelogenous leukaemia (CML) and polycythemia vera (PV), referred to us for the management of non-healing perimalleolar ulcers of varying durations." | 3.73 | Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls. ( Gupta, K; Jain, V; Nagpal, N, 2005) |
| "We report a series of 9 patients, 6 men and 3 women, who presented nail hyperpigmentation arising between 6 and 24 months from the start of hydroxyurea therapy." | 3.71 | Nail pigmentation caused by hydroxyurea: report of 9 cases. ( Aste, N; Biggio, P; Contu, F; Fumo, G, 2002) |
| "Hydroxyurea is a cytostatic agent used in patients with myeloproliferative disorders that may produce nail hyperpigmentation, most frequently longitudinal melanonychia." | 3.70 | Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. ( de Unamuno, P; Hernández-Martín, A; Ros-Forteza, S, 1999) |
| "Hydroxyurea has documented laboratory efficacy with increases in Hb and HbF; treatment also significantly reduces the number of painful episodes, acute chest syndrome, transfusions, and hospitalizations." | 2.49 | Hydroxycarbamide: clinical aspects. ( Ware, RE, 2013) |
| "Hydroxyurea is a chemotherapeutic agent that is used in the treatment of various hematological diseases including chronic myelogenous leukemia, polycythemia vera, and sickle cell anemia." | 1.51 | Hydroxyurea-induced hyperpigmentation with iron deposition. ( Klimas, NK; Koshelev, MV; Lee, KP; Sanyal, S; Vangipuram, RK, 2019) |
| "Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis." | 1.40 | Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. ( Gupta, A; Karanth, SS; Prabhu, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Divyashree, K | 1 |
| Gupta, R | 1 |
| Chandana, VS | 1 |
| Pannu, AK | 1 |
| Lee, KP | 1 |
| Vangipuram, RK | 1 |
| Klimas, NK | 1 |
| Sanyal, S | 1 |
| Koshelev, MV | 1 |
| Bulte, CA | 1 |
| Hoegler, KM | 1 |
| Kutlu, Ö | 1 |
| Khachemoune, A | 1 |
| Schoenfeld, J | 1 |
| Tulbert, BH | 1 |
| Cusack, CA | 1 |
| Osemwota, O | 1 |
| Uhlemann, J | 1 |
| Rubin, A | 1 |
| Saito, A | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Ishitsuka, Y | 1 |
| Watanabe, R | 1 |
| Okiyama, N | 1 |
| Fujimoto, M | 1 |
| Ware, RE | 2 |
| Karanth, SS | 1 |
| Gupta, A | 1 |
| Prabhu, M | 1 |
| Saraceno, R | 1 |
| Teoli, M | 1 |
| Chimenti, S | 1 |
| Jain, V | 1 |
| Gupta, K | 1 |
| Nagpal, N | 1 |
| Kluger, N | 1 |
| Naud, M | 1 |
| Françès, P | 1 |
| Su, PH | 1 |
| How, CK | 1 |
| Yen, DH | 1 |
| Huang, MS | 1 |
| Neynaber, S | 1 |
| Wolff, H | 1 |
| Plewig, G | 1 |
| Wienecke, R | 1 |
| Ceulen, RP | 1 |
| Frank, J | 1 |
| Poblete-Gutiérrez, P | 1 |
| Pirard, C | 1 |
| Michaux, JL | 1 |
| Bourlond, A | 1 |
| Gropper, CA | 1 |
| Don, PC | 1 |
| Sadjadi, MM | 1 |
| Kwong, YL | 1 |
| Liebschutz, S | 1 |
| Quéré, I | 1 |
| Lukasik, E | 1 |
| Dereure, O | 1 |
| Rondes, J | 1 |
| Janbon, C | 1 |
| Hernández-Martín, A | 1 |
| Ros-Forteza, S | 1 |
| de Unamuno, P | 1 |
| Laughon, SK | 1 |
| Shinn, LL | 1 |
| Nunley, JR | 1 |
| O'branski, EE | 1 |
| Prose, NS | 1 |
| Kinney, TR | 1 |
| Joyner, S | 1 |
| Lee, D | 1 |
| Hay, P | 1 |
| Lau, R | 1 |
| Aste, N | 2 |
| Fumo, G | 1 |
| Contu, F | 1 |
| Biggio, P | 1 |
2 reviews available for hydroxyurea and Hyperpigmentation
| Article | Year |
|---|---|
Hydroxyurea: a reappraisal of its cutaneous side effects and their management.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Hyperpigmentation; Leg Ulcer; Skin; Skin Neoplasms | 2021 |
Hydroxycarbamide: clinical aspects.
Topics: Agranulocytosis; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials as Topic; Developing Coun | 2013 |
21 other studies available for hydroxyurea and Hyperpigmentation
| Article | Year |
|---|---|
Hydroxyurea-induced lunular hyperpigmentation.
Topics: Humans; Hydroxyurea; Hyperpigmentation; Nails | 2022 |
Hydroxyurea-induced hyperpigmentation with iron deposition.
Topics: Aged; Humans; Hydroxyurea; Hyperpigmentation; Iron; Male; Microscopy, Electrochemical, Scanning; Nuc | 2019 |
Transverse melanonychia and palmar hyperpigmentation secondary to hydroxyurea therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; Female; Hand; Humans; Hydroxyurea | 2017 |
Twenty-Nail Transverse Melanonychia Induced by Hydroxyurea: Case Report and Review of the Literature.
Topics: Anemia, Sickle Cell; Diagnosis, Differential; Female; Humans; Hydroxyurea; Hyperpigmentation; Middle | 2017 |
Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
Topics: Aged; Female; Humans; Hydroxyurea; Hyperpigmentation; Melanoma; Nail Diseases; Nucleic Acid Synthesi | 2018 |
Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis.
Topics: Female; Humans; Hydroxyurea; Hyperpigmentation; Middle Aged; Nail Diseases; Nails; Stroke; Thrombocy | 2014 |
Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.
Topics: Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxy | 2008 |
Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls.
Topics: Aged; Antineoplastic Agents; Chronic Disease; Humans; Hydroxyurea; Hyperpigmentation; Leukemia, Myel | 2005 |
Toenails melanonychia induced by hydroxyurea.
Topics: Aged; Antisickling Agents; Diagnosis, Differential; Drug Eruptions; Female; Humans; Hydroxyurea; Hyp | 2012 |
Melanonychia secondary to hydroxyurea.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Platelet Agg | 2012 |
[Longitudinal melanonychia induced by hydroxyurea therapy].
Topics: Aged; Aged, 80 and over; Diagnosis, Differential; Female; Humans; Hydroxyurea; Hyperpigmentation; Le | 2004 |
Nail pigmentation due to hydroxycarbamide.
Topics: Humans; Hydroxyurea; Hyperpigmentation; Male; Middle Aged; Nail Diseases; Nucleic Acid Synthesis Inh | 2007 |
[Longitudinal melanonychia and hydroxyurea].
Topics: Female; Hand Dermatoses; Humans; Hydroxyurea; Hyperpigmentation; Leukemia, Myelogenous, Chronic, BCR | 1994 |
Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera.
Topics: Female; Humans; Hydroxyurea; Hyperpigmentation; Middle Aged; Mouth Diseases; Mouth Mucosa; Nail Dise | 1993 |
Hydroxyurea-induced nail pigmentation.
Topics: Aged; Enzyme Inhibitors; Female; Fingers; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Thr | 1996 |
[Hyperalgesic malleolar ulcer: recovery on the withdrawal of hydroxyurea].
Topics: Ankle; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperalgesia; Hyperpigmentation; Leg Ulcer; M | 1998 |
Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea.
Topics: Aged; Humans; Hydroxyurea; Hyperpigmentation; Male; Nail Diseases; Thrombocytopenia | 1999 |
Melanonychia and mucocutaneous hyperpigmentation due to hydroxyurea use in an HIV-infected patient.
Topics: Antiviral Agents; Female; HIV Infections; Humans; Hydroxyurea; Hyperpigmentation; Melanosis; Middle | 2000 |
Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Hyperpigme | 2001 |
Hydroxyurea-induced nail pigmentation in HIV patients.
Topics: Adult; Anti-HIV Agents; Black People; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma | 1999 |
Nail pigmentation caused by hydroxyurea: report of 9 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Female; Follow-Up Studies; He | 2002 |